Belumosudil Mesylate

CHEMBL4802130 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

548.6 g/mol

LogP

—

Phase

4

The mesylate salt of belumosudil, used to treat chronic graft-versus-host disease via the same ROCK2 inhibition mechanism as the parent compound.

분자량

548.6000 g/mol

TPSA

168.00 Å²

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1.CS(=O)(=O)O

InChI

InChI=1S/C26H24N6O2.CH4O3S/c1-16(2)28-24(33)15-34-20-7-5-6-17(13-20)25-30-23-9-4-3-8-21(23)26(31-25)29-19-10-11-22-18(12-19)14-27-32-22;1-5(2,3)4/h3-14,16H,15H2,1-2H3,(H,27,32)(H,28,33)(H,29,30,31);1H3,(H,2,3,4)

Molecular Formula

C27H28N6O5S

HBD / HBA

4 / 9

회전 가능 결합

7

무거운 원자

39

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

The mesylate salt of belumosudil, used to treat chronic graft-versus-host disease via the same ROCK2 inhibition mechanism as the parent compound.

Yes, Belumosudil Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4802130. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 146025939. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Belumosudil Mesylate PillFYI에서

구조

핵심 데이터

분자식: C27H28N6O5S

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.